Eli Lilly Under Pressure From Weight Loss Drug Pricing Comments

9 days ago

Carol Master / Bailey Lip Schultz

"So, can we talk about the JLP1 drugs, most notably LLY, Eli Liy? Yes, Eli Liy. The stock is down about 2% right now. It's been falling all day after Trump said that the price of Ozmpic could come down to just $150 a month. So, Eli Liy, they don't make OMPic. That's Novo Nordisk. that stock uh trading in Europe was down as well, but we're seeing Eli Liy, they have similar weight loss drugs."

The commentary focuses on Eli Lilly's stock weakness in response to external commentary on weight loss drug pricing. The discussion notes that while Eli Lilly is not directly tied to the drug mentioned, market sentiment is affected due to comparisons with competitors.

Related Stocks